TY - JOUR
T1 - KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma
T2 - Does It Influence Prognosis or Stage of Disease at Presentation?
AU - Shen, Henry
AU - Lundy, Joanne
AU - Strickland, Andrew H.
AU - Harris, Marion
AU - Swan, Michael
AU - Desmond, Christopher
AU - Jenkins, Brendan J.
AU - Croagh, Daniel
N1 - Funding Information:
This research was funded by a Monash Partners Comprehensive Cancer Consortium (MPCCC) research grant and an Epworth Medical Foundation (EMF) research grant. Additional funding was obtained from Amgen, who also supplied the study drug for the prospective cohort study (Monash Health HREC Ref: 16584A) from which some of our retrospective study patient samples and data were taken from.
Funding Information:
This study received partial funding from Amgen. The funder had no role in the design, execution, interpretation, or writing of this study. However, the funder had the following involvement with the prospective cohort study (Monash Health HREC Ref: 16584A) from which some of our retrospective study patient samples and data were taken from: review of study design, provision of study drug and partial funding for study procedures.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/10
Y1 - 2022/10
N2 - Background: KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinoma (PDAC), one of the leading global causes of cancer death. This retrospective cohort study aims to investigate whether detection of the KRAS G12D mutation subtype in PDAC patients is a determinant of prognosis across all stages of disease. Methods: We reviewed the medical records of 231 patients presenting with PDAC at a large tertiary hospital, and compared survival using the Kaplan Meier, log-rank test and Cox proportional hazards regression model. Results: KRAS G12D mutation subtype was not significantly associated with poorer survival compared across the whole population of PDAC patients (p = 0.107; HR 1.293 95% CI (0.946–1.767)). However, KRAS G12D patients who were resectable had a shorter median survival time of 356 days compared to all other genotypes (median survival 810 days) (p = 0.019; HR 1.991 95% CI (1.121–3.537)). Conclusions: KRAS G12D patients who were resectable at diagnosis had shorter survival compared to all other PDAC patients. These data suggest that KRAS G12D may be a clinically useful prognostic biomarker of PDAC.
AB - Background: KRAS G12D mutation subtype is present in over 40% of pancreatic ductal adenocarcinoma (PDAC), one of the leading global causes of cancer death. This retrospective cohort study aims to investigate whether detection of the KRAS G12D mutation subtype in PDAC patients is a determinant of prognosis across all stages of disease. Methods: We reviewed the medical records of 231 patients presenting with PDAC at a large tertiary hospital, and compared survival using the Kaplan Meier, log-rank test and Cox proportional hazards regression model. Results: KRAS G12D mutation subtype was not significantly associated with poorer survival compared across the whole population of PDAC patients (p = 0.107; HR 1.293 95% CI (0.946–1.767)). However, KRAS G12D patients who were resectable had a shorter median survival time of 356 days compared to all other genotypes (median survival 810 days) (p = 0.019; HR 1.991 95% CI (1.121–3.537)). Conclusions: KRAS G12D patients who were resectable at diagnosis had shorter survival compared to all other PDAC patients. These data suggest that KRAS G12D may be a clinically useful prognostic biomarker of PDAC.
KW - carcinoma
KW - pancreatic ductal
KW - point mutation
KW - prognosis
KW - proto-oncogene proteins p21(ras)
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85139777835&partnerID=8YFLogxK
U2 - 10.3390/cells11193175
DO - 10.3390/cells11193175
M3 - Article
C2 - 36231137
AN - SCOPUS:85139777835
SN - 2073-4409
VL - 11
JO - Cells
JF - Cells
IS - 19
M1 - 3175
ER -
